Latest news with #GERN
Yahoo
08-08-2025
- Business
- Yahoo
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this drugmaker would post a loss of $0.04 per share when it actually produced a loss of $0.03, delivering a surprise of +25%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Geron, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $49.04 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.35%. This compares to year-ago revenues of $0.88 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Geron shares have lost about 66.1% since the beginning of the year versus the S&P 500's gain of 7.1%. What's Next for Geron? While Geron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Geron was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $52.47 million in revenues for the coming quarter and -$0.12 on $197.43 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. TELA Bio, Inc. (TELA), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 11. This company is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of +64.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. TELA Bio, Inc.'s revenues are expected to be $20.55 million, up 27.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Geron Corporation (GERN) : Free Stock Analysis Report TELA Bio, Inc. (TELA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
07-08-2025
- Business
- Yahoo
Emerson Electric Co (EMR) Q3 2025 Earnings Call Highlights: Strong Profitability Amid Market ...
Revenue: Underlying sales growth of 3% for the third quarter. Adjusted Earnings Per Share (EPS): $1.52, a 6% increase year-over-year. Free Cash Flow: $970 million, with a margin of 21.3%. Adjusted Segment EBITDA Margin: 27.1%, impacted by 40 basis points due to tariffs. Backlog: Increased to $7.6 billion, with a book-to-bill ratio of 1%. Price Contribution: 2.5 points in the quarter. Fourth Quarter Guidance: Expected underlying sales growth of 5% to 6% and adjusted EPS between $1.58 and $1.62. Full Year Guidance: Underlying sales expected to be up approximately 3.5%, with adjusted EPS of approximately $6 per share. Warning! GuruFocus has detected 5 Warning Signs with GERN. Release Date: August 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Emerson Electric Co (NYSE:EMR) reported strong profitability with an adjusted earnings per share of $1.52, meeting the top end of their guidance. The company announced a strategic collaboration with TotalEnergies, enhancing their enterprise operations platform and showcasing their innovation in automation. Emerson's industrial software annual contract value (ACV) grew double digits, ending the quarter at $1.5 billion. The Test & Measurement segment showed significant recovery, with orders up 16%, indicating strong market demand. Emerson's free cash flow generation was better than expected, resulting in a margin of 21.3%. Negative Points Sales growth was impacted by easing surcharges, resulting in underlying sales growth of only 3%, which fell short of guidance. The Intelligent Devices segment faced profitability challenges due to tariffs and unexpected foreign exchange impacts. Europe's sales were down 7%, indicating regional challenges in market performance. The discrete automation market, particularly in automotive and packaging in Western Europe and China, remains relatively depressed. The tariff environment remains dynamic, with Emerson's annualized gross incremental tariff impact now estimated at $210 million, affecting profitability. Q & A Highlights Q: Can you explain the margin dynamics for Intelligent Devices, considering the impact of tariffs and FX? A: The Intelligent Devices segment experienced a margin decline due to tariffs and unexpected FX impacts. When excluding these factors, margins were up by 20 basis points. Tariffs primarily affected this segment, unlike Control Systems and Software, which had minimal tariff exposure. (Surendralal Karsanbhai, CEO) Q: What is driving the recovery in the Test & Measurement segment, and is it broad-based? A: The recovery in Test & Measurement is broad-based across all segments and regions. The portfolio business, aerospace defense, semiconductor, and automotive sectors are all contributing positively. Asia, particularly China, is leading the recovery, followed by North America and Europe. (Surendralal Karsanbhai, CEO; Ram Krishnan, COO) Q: How did orders trend throughout the quarter, and what is the outlook for software growth next year? A: Orders remained consistent with a mid-single-digit exit rate, with some fluctuations due to timing. For software, AspenTech's ACV is expected to continue growing in high single to double digits, with consistent growth in the Process segment. (Surendralal Karsanbhai, CEO; Ram Krishnan, COO) Q: What is the outlook for the power vertical, and can growth remain elevated? A: The power vertical is expected to sustain high teens growth over the next couple of years, driven by opportunities in generation and transmission distribution. The focus has shifted to project pursuit and market expansion, supported by strong customer relationships. (Surendralal Karsanbhai, CEO; Ram Krishnan, COO) Q: Can you provide more details on the Control Systems and Software segment's performance and outlook? A: The segment saw mid-single-digit growth, with some lumpiness due to project timing and ASC 606 recognition. AspenTech's ACV growth remains strong, and the systems business continues to perform well. Overall, the segment is expected to achieve high-end growth within the 4% to 7% range. (Michael Baughman, CFO; Ram Krishnan, COO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
10-05-2025
- Business
- Associated Press
GERN Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Geron Corporation (GERN) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - May 10, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that securities class action lawsuits have been filed against Geron Corporation ('Geron') ( NASDAQ: GERN ) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is May 12, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Geron losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaints allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendants created the false impression that they possessed reliable information pertaining to Geron's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations; (2) in truth, Geron's optimistic reports of its primary product, RYTELO's, launch success and potential growth fell short of reality as the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than Defendants had implied; (3) RYTELO lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting; and (4) as a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. THE LEAD PLAINTIFF PROCESS: Geron investors may, no later than May 12, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Geron investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Business Wire
09-05-2025
- Business
- Business Wire
GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Geron Corporation ('Geron' or 'the Company') (NASDAQ: GERN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Geron gave investors the false impression that it had reliable information about its projected revenue outlook and anticipated growth. The Company's optimistic reports of Rytelo's launch and potential growth were far too optimistic. The Company failed to inform investors that Rytelo lacked necessary patient awareness for the Company to capitalize on what it had claimed was a significant unmet need for the drug. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Geron, investors suffered damages. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Washington Post
07-05-2025
- Business
- Washington Post
Geron: Q1 Earnings Snapshot
FOSTER CITY, Calif. — FOSTER CITY, Calif. — Geron Corp. (GERN) on Wednesday reported a loss of $19.8 million in its first quarter. On a per-share basis, the Foster City, California-based company said it had a loss of 3 cents.
